DekaBank Deutsche Girozentrale Purchases 220,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

DekaBank Deutsche Girozentrale lifted its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 1,359.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 236,178 shares of the biotechnology company’s stock after purchasing an additional 220,000 shares during the period. DekaBank Deutsche Girozentrale’s holdings in ADMA Biologics were worth $1,068,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ADMA. JPMorgan Chase & Co. boosted its position in ADMA Biologics by 360.0% during the 1st quarter. JPMorgan Chase & Co. now owns 79,106 shares of the biotechnology company’s stock worth $144,000 after buying an additional 61,909 shares during the period. Raymond James & Associates lifted its holdings in shares of ADMA Biologics by 24.0% during the first quarter. Raymond James & Associates now owns 199,984 shares of the biotechnology company’s stock worth $366,000 after purchasing an additional 38,715 shares during the period. Bank of New York Mellon Corp grew its stake in shares of ADMA Biologics by 79.6% in the first quarter. Bank of New York Mellon Corp now owns 83,401 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 36,967 shares during the last quarter. Bank of Montreal Can acquired a new stake in ADMA Biologics in the first quarter valued at $1,665,000. Finally, BlackRock Inc. raised its position in ADMA Biologics by 0.8% during the 1st quarter. BlackRock Inc. now owns 4,107,382 shares of the biotechnology company’s stock worth $7,517,000 after purchasing an additional 31,791 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Mizuho raised their price objective on ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. HC Wainwright restated a “buy” rating and set a $7.50 price target (up previously from $6.00) on shares of ADMA Biologics in a report on Tuesday, March 26th. Finally, Cantor Fitzgerald boosted their price target on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $7.88.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 183,008 shares of ADMA Biologics stock in a transaction on Friday, March 15th. The shares were sold at an average price of $6.01, for a total value of $1,099,878.08. Following the completion of the sale, the director now directly owns 2,577,387 shares of the company’s stock, valued at $15,490,095.87. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold a total of 639,895 shares of company stock valued at $3,927,169 over the last ninety days. 6.00% of the stock is owned by corporate insiders.

ADMA Biologics Trading Down 3.2 %

NASDAQ ADMA opened at $6.02 on Monday. The stock has a market capitalization of $1.37 billion, a P/E ratio of -46.31 and a beta of 0.46. The business has a 50 day simple moving average of $5.86 and a 200 day simple moving average of $4.68. The company has a debt-to-equity ratio of 1.04, a current ratio of 5.16 and a quick ratio of 1.69. ADMA Biologics, Inc. has a one year low of $3.06 and a one year high of $6.76.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. The firm had revenue of $73.90 million for the quarter, compared to analysts’ expectations of $73.50 million. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. Research analysts expect that ADMA Biologics, Inc. will post 0.3 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.